Ribozyme starts Phase II Angiozyme trial

RZYM began a U.S. Phase II trial to study the combination of carboplatin and paclitaxel with its Angiozyme synthetic ribozyme inhibitor of vascular endothelial growth factor receptor (VEGFr) in cancer...